T1期膀胱癌亚分期现状的系统综述
该研究于2024年3月检索MEDLINE、EMBASE和Cochrane图书馆数据库,遵循PRISMA指南,纳入1990年至2024年发表的63项研究共8328例接受T1亚分期的膀胱肿瘤患者。T1亚分期是肿瘤学结局的强预测因子,微米法在可行性和预后价值方面似乎比组织形态学方法更具可重复性和精确性,但目前缺乏标准化、经验证、统一的亚分期报告系统。
要点
- T1亚分期是肿瘤学结局的强预测因子,更晚期与更差预后及需要更根治性治疗相关。
- 亚分期方法大致分为组织形态学(基于解剖)和微米法(半定量)两类。
- 微米法在可行性和预后价值方面似乎比组织形态学方法更具可重复性和精确性。
核心结论
- T1亚分期是肿瘤学结局的强预测因子。
- 微米法在可行性和预后价值方面似乎比组织形态学方法更具可重复性和精确性。
- 该技术的标准化和验证可能改善膀胱癌治疗算法。
研究设计与样本
- 系统综述,检索MEDLINE、EMBASE和Cochrane图书馆数据库,检索时间为2024年3月,遵循PRISMA指南声明,仅检索英文文献。
- 最终纳入1990年至2024年发表的63项研究,共8328例接受T1亚分期的膀胱肿瘤患者。
主要发现
- 已开发多种亚分期方法,大致分为组织形态学(基于解剖)和微米法(半定量)技术。
- 更晚期与更差预后及需要更根治性治疗一致相关。
- 缺乏标准化、经验证、统一的亚分期报告系统。
关键数值与推荐
- 共63项研究、8328例接受T1亚分期的膀胱肿瘤患者被纳入最终综述。
- 文献检索于2024年3月进行,仅纳入英文文献。
局限性
- 缺乏标准化、经验证、统一的亚分期报告系统。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To conduct a systematic review on the current state of T1 bladder tumor substaging. These neoplasms display significant heterogeneity in oncological behavior and prognosis, leading to the proposal of various substaging methods. Our aim was to investigate the potential diagnostic and prognostic value of substaging in stage T1 bladder cancer for better oncologic outcomes. METHODS: A literature search using MEDLINE, EMBASE and Cochrane Library databases was conducted in March 2024 to identify relevant studies on T1 urothelial bladder cancer staging. A systematic review of included articles was performed following the PRISMA guideline statement. Literature search was conducted in English. RESULTS: Overall, 63 studies published between 1990 and 2024 were included for final review including a total number of 8328 bladder tumor patients subject to T1 substaging. Various substaging methods have been developed, broadly classified into histometric (anatomy-based) and micrometric (semiquantitative) techniques. Advanced stages have been consistently associated with worse prognosis and need for a more radical therapeutic approach. A standardized, validated, unified substaging report system is lacking. CONCLUSION: T1 substaging is a strong predictor of oncologic outcomes. Micrometric methods seem to be more reproducible and precise than histometric techniques in terms of feasibility and prognostic value. Standardization and validation of the technique could potentially enhance the bladder cancer treatment algorithm.
引用
- Pérez-Aizpurua X, Monzó-Gardiner JI, Popescu OB, et al. A Systematic Review on the Current Landscape of T1 Bladder Cancer Substaging. Urology. 2024. PMID: 39389368. doi:10.1016/j.urology.2024.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。